PSU Profiles
Loading...
Keywords
Last Name
Institution

Raymond J. Hohl

TitleDirector
InstitutionPenn State Cancer Institute
Address500 University Drive Hershey, PA 17033
Phone717-531-4034
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Director, Penn State Cancer Institute
    Professor of Medicine and Pharmacology


    RESEARCH INTERESTS:

    Dr. Hohl's research interests focus on understanding the interactions between mevalonic acid and cholesterol biosynthesis and the proliferation of acute myeloid leukemia cells. These studies investigate the relative affinities of various growth regulating proteins, such as RAS and KREV1, for the isoprene intermediates of the mevalonic acid to cholesterol biosynthetic pathway. His clinical interests involve evaluation of the potential role for pharmacologic inhibitors of this biosynthetic pathway in the treatment of various hematologic malignancies and solid tumors. Additionally, he has continued interest in studying how various erythrocyte enzymothathies predispose the human red blood cell to drug-induced oxidative damage.

    EDUCATION AND TRAINING:

    1978 BS (Biochemistry) University of Illinois, Urbana
    1984 MD Rush Medical College, Rush University
    1993 PhD (Pharmacology) Graduate College, Rush University


    Postgraduate Medical Education
    1984-87 Residency in Internal Medicine University of Chicago
    1987-91 Fellowship in Hematology/Oncology University of Chicago


    HONORS and AWARDS:
    1988 Paul E. Carson, Pharmacology Award
    1991 Carver Clinician, Scientist Award
    1992 Clinical Pharmacology Faculty Development Award, Pharma Foundation
    1992 Young Investigator Award, American Society of Clinical Oncology
    1995 Outstanding Research Award in Clinical Pharmacology, Central Society for Clinical Research
    1996 Outstanding Research Award, GCRC Program Directors' Association
    2001 Laureate Award, American College of Physicians


    MEMBERSHIPS:

    1998 - 2001 Vice Chair, Hematologic and Neoplastic Diseases, Scientific Section, American Society for Clinical Pharmacology and Therapeutics
    1998 - 2012 Vice Chair, Cancer and Leukemia Group B Institutional Performance Evaluation Committee
    2000 - 2003 Member, Education Committee of the American Society for Clinical Oncology
    2001 - 2003 Chair, Hematologic and Neoplastic Diseases, Scientific Section, American Society for Clinical Pharmacology and Therapeutics
    2003 - 2006 Member, Board of Directors, American Society for Clinical Pharmacology and Therapeutics
    2009 - present Delegate and Model Guidelines Expert Panel, United State Pharmacopeia
    2006 – 2008 President, Iowa Oncology Society
    2010 - 2011 President, American Society for Clinical Pharmacology and Therapeutics
    2013- present Member, American Society of Hematology Committee on Government Affairs


    EDITORSHIPS:

    2000 - present Editorial Advisory Board, Lipids
    2006 - present Associate Editor, Clinical Pharmacology and Therapeutics
    2015 - present Editorial Board, Journal of Global Oncology

    JOURNAL REVIEWER:

    1992-present Cancer Research
    1994-present Lipids
    1995-present P & T News
    1996-present Journal of Organic Chemistry
    1996-present Journal of Pharmacology & Experimental Therapeutics
    1996-present Annals of Otology, Rhinology, and Laryngology
    1997-present Biochimica et. Biophysical ACTA
    1997-present Cancer Chemotherapy and Pharmacology
    1998-present Clinical Cancer Research
    2002-present The Journal of Laboratory and Clinical Medicine
    2002-present Atherosclerosis, Thrombosis and Vascular Biology
    2003-present American Journal of Hematology
    2003-present Gynecologic and Obstetric Investigation
    2004-present Clinical Pharmacology and Therapeutics
    2006-present Molecular Pharmacology


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Schoenfeld JD, Sibenaller ZA, Mapuskar KA, Wagner BA, Cramer-Morales KL, Furqan M, Sandhu S, Carlisle TL, Smith MC, Abu Hejleh T, Berg DJ, Zhang J, Keech J, Parekh KR, Bhatia S, Monga V, Bodeker KL, Ahmann L, Vollstedt S, Brown H, Kauffman EPS, Schall ME, Hohl RJ, Clamon GH, Greenlee JD, Howard MA, Schultz MK, Smith BJ, Riley DP, Domann FE, Cullen JJ, Buettner GR, Buatti JM, Spitz DR, Allen BG. O2·- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell. 2017 08 14; 32(2):268. PMID: 28810149.
      View in: PubMed
    2. Zhu L, Kong Y, Zhang J, Claxton DF, Ehmann WC, Rybka WB, Palmisiano ND, Wang M, Jia B, Bayerl M, Schell TD, Hohl RJ, Zeng H, Zheng H. Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia. J Hematol Oncol. 2017 Jun 19; 10(1):124. PMID: 28629373.
      View in: PubMed
    3. Lee J, Blumenthal GM, Hohl RJ, Huang SM. Cancer Therapy: Shooting for the Moon. Clin Pharmacol Ther. 2017 May; 101(5):552-558. PMID: 28418166.
      View in: PubMed
    4. Schoenfeld JD, Sibenaller ZA, Mapuskar KA, Wagner BA, Cramer-Morales KL, Furqan M, Sandhu S, Carlisle TL, Smith MC, Abu Hejleh T, Berg DJ, Zhang J, Keech J, Parekh KR, Bhatia S, Monga V, Bodeker KL, Ahmann L, Vollstedt S, Brown H, Shanahan Kauffman EP, Schall ME, Hohl RJ, Clamon GH, Greenlee JD, Howard MA, Schultz MK, Smith BJ, Riley DP, Domann FE, Cullen JJ, Buettner GR, Buatti JM, Spitz DR, Allen BG. O2·- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell. 2017 Apr 10; 31(4):487-500.e8. PMID: 28366679.
      View in: PubMed
    5. Ferguson SD, Xiu J, Weathers SP, Zhou S, Kesari S, Weiss SE, Verhaak RG, Hohl RJ, Barger GR, Reddy SK, Heimberger AB. GBM-associated mutations and altered protein expression are more common in young patients. Oncotarget. 2016 Oct 25; 7(43):69466-69478. PMID: 27579614.
      View in: PubMed
    6. Reilly JE, Neighbors JD, Hohl RJ. Targeting protein geranylgeranylation slows tumor development in a murine model of prostate cancer metastasis. Cancer Biol Ther. 2017 Nov 02; 18(11):872-882. PMID: 27624889.
      View in: PubMed
    7. Hohl RJ. Anticoagulants: Major Advances Without Clear Consensus. Clin Pharmacol Ther. 2016 Aug; 100(2):116-8. PMID: 27393187.
      View in: PubMed
    8. Raje NS, Faber EA, Richardson PG, Schiller G, Hohl RJ, Cohen AD, Forero A, Carpenter S, Nguyen TS, Conti I, Kaiser CJ, Cronier DM, Wooldridge JE, Anderson KC. Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma. Clin Cancer Res. 2016 Dec 01; 22(23):5688-5695. PMID: 27287072.
      View in: PubMed
    9. Kuder CH, Weivoda MM, Zhang Y, Zhu J, Neighbors JD, Wiemer DF, Hohl RJ. 3-Deoxyschweinfurthin B Lowers Cholesterol Levels by Decreasing Synthesis and Increasing Export in Cultured Cancer Cell Lines. Lipids. 2015 Dec; 50(12):1195-207. PMID: 26494560.
      View in: PubMed
    10. Ferguson NN, Thomas CP, Hohl RJ, Syrbu SI, Stone MS, Wanat KA. Primary Cutaneous Polymorphic EBV-Associated Posttransplant Lymphoproliferative Disorder After a Renal Transplant and Review of the Literature. Am J Dermatopathol. 2015 Oct; 37(10):790-4. PMID: 25747810.
      View in: PubMed
    11. Reilly JE, Neighbors JD, Tong H, Henry MD, Hohl RJ. Targeting geranylgeranylation reduces adrenal gland tumor burden in a murine model of prostate cancer metastasis. Clin Exp Metastasis. 2015 Aug; 32(6):555-66. PMID: 26070429; PMCID: PMC4819324.
    12. Sheehy RM, Kuder CH, Bachman Z, Hohl RJ. Calcium and P-glycoprotein independent synergism between schweinfurthins and verapamil. Cancer Biol Ther. 2015; 16(8):1259-68. PMID: 26046259; PMCID: PMC4622842.
    13. Osborn-Heaford HL, Murthy S, Gu L, Larson-Casey JL, Ryan AJ, Shi L, Glogauer M, Neighbors JD, Hohl R, Carter AB. Targeting the isoprenoid pathway to abrogate progression of pulmonary fibrosis. Free Radic Biol Med. 2015 Sep; 86:47-56. PMID: 25958207; PMCID: PMC4554879.
    14. Reilly JE, Zhou X, Tong H, Kuder CH, Wiemer DF, Hohl RJ. In vitro studies in a myelogenous leukemia cell line suggest an organized binding of geranylgeranyl diphosphate synthase inhibitors. Biochem Pharmacol. 2015 Jul 15; 96(2):83-92. PMID: 25952057; PMCID: PMC4831703.
    15. Hohl RJ. Oncology trial design: More accurately and efficiently advancing the field. Clin Pharmacol Ther. 2015 May; 97(5):430-2. PMID: 25684240.
      View in: PubMed
    16. Holstein SA, Bigelow JC, Olson RD, Vestal RE, Walsh GM, Hohl RJ. Phase I and pharmacokinetic study of the novel anthracycline derivative 5-imino-13-deoxydoxorubicin (GPX-150) in patients with advanced solid tumors. Invest New Drugs. 2015 Jun; 33(3):594-602. PMID: 25698442.
      View in: PubMed
    17. Hohl RJ. Drug development (and academic medicine): charting the course forward. Clin Pharmacol Ther. 2014 Nov; 96(5):519-22. PMID: 25336261.
      View in: PubMed
    18. Zhou X, Reilly JE, Loerch KA, Hohl RJ, Wiemer DF. Synthesis of isoprenoid bisphosphonate ethers through C-P bond formations: Potential inhibitors of geranylgeranyl diphosphate synthase. Beilstein J Org Chem. 2014; 10:1645-50. PMID: 25161722; PMCID: PMC4142842.
    19. Hohl RJ. Personalized medicine: through the looking glass of functional imaging. Clin Cancer Res. 2013 Aug 01; 19(15):4024-6. PMID: 23785049.
      View in: PubMed
    20. Tong H, Kuder CH, Wasko BM, Hohl RJ. Quantitative determination of isopentenyl diphosphate in cultured mammalian cells. Anal Biochem. 2013 Feb 01; 433(1):36-42. PMID: 23000003.
      View in: PubMed
    21. Sokol L, Cripe L, Kantarjian H, Sekeres MA, Parmar S, Greenberg P, Goldberg SL, Bhushan V, Shammo J, Hohl R, Verma A, Garcia-Manero G, Li YP, Lowe A, Zhu J, List AF. Randomized, dose-escalation study of the p38a MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome. Leukemia. 2013 Apr; 27(4):977-80. PMID: 23032694.
      View in: PubMed
    22. Holstein SA, Hohl RJ. Is there a future for prenyltransferase inhibitors in cancer therapy? Curr Opin Pharmacol. 2012 Dec; 12(6):704-9. PMID: 22817869.
      View in: PubMed
    23. Kuder CH, Sheehy RM, Neighbors JD, Wiemer DF, Hohl RJ. Functional evaluation of a fluorescent schweinfurthin: mechanism of cytotoxicity and intracellular quantification. Mol Pharmacol. 2012 Jul; 82(1):9-16. PMID: 22461663; PMCID: PMC3382832.
    24. Malchenko S, Seftor EA, Nikolsky Y, Hasegawa SL, Kuo S, Stevens JW, Poyarkov S, Nikolskaya T, Kucaba T, Wang M, Abdulkawy H, Casavant T, Morcuende J, Buckwalter J, Hohl R, Deyoung B, Kernstine K, Bonaldo Mde F, Hendrix MJ, Soares MB, Soares VM. Putative multifunctional signature of lung metastases in dedifferentiated chondrosarcoma. Sarcoma. 2012; 2012:820254. PMID: 22448124; PMCID: PMC3289931.
    25. Messing E, Gee JR, Saltzstein DR, Kim K, diSant'Agnese A, Kolesar J, Harris L, Faerber A, Havighurst T, Young JM, Efros M, Getzenberg RH, Wheeler MA, Tangrea J, Parnes H, House M, Busby JE, Hohl R, Bailey H. A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients. Cancer Prev Res (Phila). 2012 Apr; 5(4):621-30. PMID: 22293631; PMCID: PMC3324663.
    26. Holstein SA, Hohl RJ. Therapeutic additions and possible deletions in oncology in 2011. Clin Pharmacol Ther. 2012 Jan; 91(1):15-7. PMID: 22179625.
      View in: PubMed
    27. Wiemer AJ, Wiemer DF, Hohl RJ. Geranylgeranyl diphosphate synthase: an emerging therapeutic target. Clin Pharmacol Ther. 2011 Dec; 90(6):804-12. PMID: 22048229.
      View in: PubMed
    28. Weivoda MM, Hohl RJ. Geranylgeranyl pyrophosphate stimulates PPAR? expression and adipogenesis through the inhibition of osteoblast differentiation. Bone. 2012 Feb; 50(2):467-76. PMID: 22019459.
      View in: PubMed
    29. Wasko BM, Smits JP, Shull LW, Wiemer DF, Hohl RJ. A novel bisphosphonate inhibitor of squalene synthase combined with a statin or a nitrogenous bisphosphonate in vitro. J Lipid Res. 2011 Nov; 52(11):1957-64. PMID: 21903868; PMCID: PMC3196227.
    30. Witzig TE, Tang H, Micallef IN, Ansell SM, Link BK, Inwards DJ, Porrata LF, Johnston PB, Colgan JP, Markovic SN, Nowakowski GS, Thompson CA, Allmer C, Maurer MJ, Gupta M, Weiner G, Hohl R, Kurtin PJ, Ding H, Loegering D, Schneider P, Peterson K, Habermann TM, Kaufmann SH. Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. Blood. 2011 Nov 03; 118(18):4882-9. PMID: 21725056; PMCID: PMC3208296.
    31. Waldman SA, Hohl RJ, Kearns GL, Swan SJ, Terzic A. Clinical pharmacology as a foundation for translational science. Clin Pharmacol Ther. 2011 Jul; 90(1):10-3. PMID: 21691266.
      View in: PubMed
    32. Holstein SA, Kuder CH, Tong H, Hohl RJ. Pleiotropic effects of a schweinfurthin on isoprenoid homeostasis. Lipids. 2011 Oct; 46(10):907-21. PMID: 21633866; PMCID: PMC4484234.
    33. Weivoda MM, Hohl RJ. The effects of direct inhibition of geranylgeranyl pyrophosphate synthase on osteoblast differentiation. J Cell Biochem. 2011 Jun; 112(6):1506-13. PMID: 21503955.
      View in: PubMed
    34. Weivoda MM, Hohl RJ. Effects of farnesyl pyrophosphate accumulation on calvarial osteoblast differentiation. Endocrinology. 2011 Aug; 152(8):3113-22. PMID: 21586555.
      View in: PubMed
    35. Wasko BM, Dudakovic A, Hohl RJ. Bisphosphonates induce autophagy by depleting geranylgeranyl diphosphate. J Pharmacol Exp Ther. 2011 May; 337(2):540-6. PMID: 21335425.
      View in: PubMed
    36. Holstein SA, Hohl RJ. Isoprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma cells. Leuk Res. 2011 Apr; 35(4):551-9. PMID: 20828814; PMCID: PMC3038195.
    37. Ulrich NC, Kuder CH, Hohl RJ, Wiemer DF. Biologically active biotin derivatives of schweinfurthin F. Bioorg Med Chem Lett. 2010 Nov 15; 20(22):6716-20. PMID: 20869871.
      View in: PubMed
    38. Barney RJ, Wasko BM, Dudakovic A, Hohl RJ, Wiemer DF. Synthesis and biological evaluation of a series of aromatic bisphosphonates. Bioorg Med Chem. 2010 Oct 15; 18(20):7212-20. PMID: 20832326.
      View in: PubMed
    39. Topczewski JJ, Kuder CH, Neighbors JD, Hohl RJ, Wiemer DF. Fluorescent schweinfurthin B and F analogs with anti-proliferative activity. Bioorg Med Chem. 2010 Sep 15; 18(18):6734-41. PMID: 20724169; PMCID: PMC3967504.
    40. Dandamudi UB, Adams LM, Johnson B, Bauman J, Morris S, Murray S, Webb RT, Gartner E, Hohl R, Lewis LD. Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer. Cancer Chemother Pharmacol. 2011 Apr; 67(4):783-90. PMID: 20556613.
      View in: PubMed
    41. Dudakovic A, Tong H, Hohl RJ. Geranylgeranyl diphosphate depletion inhibits breast cancer cell migration. Invest New Drugs. 2011 Oct; 29(5):912-20. PMID: 20480384.
      View in: PubMed
    42. Ulrich NC, Kodet JG, Mente NR, Kuder CH, Beutler JA, Hohl RJ, Wiemer DF. Structural analogues of schweinfurthin F: probing the steric, electronic, and hydrophobic properties of the D-ring substructure. Bioorg Med Chem. 2010 Feb 15; 18(4):1676-83. PMID: 20116262.
      View in: PubMed
    43. Holstein SA, Tong H, Kuder CH, Hohl RJ. Quantitative determination of geranyl diphosphate levels in cultured human cells. Lipids. 2009 Nov; 44(11):1055-62. PMID: 19856009.
      View in: PubMed
    44. Byrd JC, Peterson BL, Rai KR, Hurd D, Hohl R, Perry MC, Gockerman J, Nattam S, Larson RA. Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. Leuk Lymphoma. 2009 Oct; 50(10):1589-96. PMID: 19863336.
      View in: PubMed
    45. Holstein SA, Hohl RJ. Vascular medicine: a look forward. Clin Pharmacol Ther. 2009 Aug; 86(2):117-9. PMID: 19621001.
      View in: PubMed
    46. Holstein SA, Tong H, Hohl RJ. Differential activities of thalidomide and isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells. Leuk Res. 2010 Mar; 34(3):344-51. PMID: 19646757; PMCID: PMC4228479.
    47. Wiemer AJ, Hohl RJ, Wiemer DF. The intermediate enzymes of isoprenoid metabolism as anticancer targets. Anticancer Agents Med Chem. 2009 Jun; 9(5):526-42. PMID: 19519294.
      View in: PubMed
    48. Kuder CH, Neighbors JD, Hohl RJ, Wiemer DF. Synthesis and biological activity of a fluorescent schweinfurthin analogue. Bioorg Med Chem. 2009 Jul 01; 17(13):4718-23. PMID: 19464190.
      View in: PubMed
    49. Chanan-Khan AA, Niesvizky R, Hohl RJ, Zimmerman TM, Christiansen NP, Schiller GJ, Callander N, Lister J, Oken M, Jagannath S. Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma. Leuk Lymphoma. 2009 Apr; 50(4):559-65. PMID: 19373653.
      View in: PubMed
    50. Miller AA, Murry DJ, Owzar K, Hollis DR, Kennedy EB, Abou-Alfa G, Desai A, Hwang J, Villalona-Calero MA, Dees EC, Lewis LD, Fakih MG, Edelman MJ, Millard F, Frank RC, Hohl RJ, Ratain MJ. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol. 2009 Apr 10; 27(11):1800-5. PMID: 19255312; PMCID: PMC2668705.
    51. Holstein SA, Stokes JB, Hohl RJ. Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia. Leuk Res. 2009 Feb; 33(2):344-7. PMID: 18835038.
      View in: PubMed
    52. McLennan G, Clarke L, Hohl RJ. Imaging as a biomarker for therapy response: cancer as a prototype for the creation of research resources. Clin Pharmacol Ther. 2008 Oct; 84(4):433-6. PMID: 18802422.
      View in: PubMed
    53. Tong H, Wiemer AJ, Neighbors JD, Hohl RJ. Quantitative determination of farnesyl and geranylgeranyl diphosphate levels in mammalian tissue. Anal Biochem. 2008 Jul 15; 378(2):138-43. PMID: 18457649.
      View in: PubMed
    54. Rosenberg JE, Halabi S, Sanford BL, Himelstein AL, Atkins JN, Hohl RJ, Millard F, Bajorin DF, Small EJ. Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207. Ann Oncol. 2008 May; 19(5):946-50. PMID: 18272914.
      View in: PubMed
    55. Wiemer AJ, Yu JS, Shull LW, Barney RJ, Wasko BM, Lamb KM, Hohl RJ, Wiemer DF. Pivaloyloxymethyl-modified isoprenoid bisphosphonates display enhanced inhibition of cellular geranylgeranylation. Bioorg Med Chem. 2008 Apr 01; 16(7):3652-60. PMID: 18308574.
      View in: PubMed
    56. Dudakovic A, Wiemer AJ, Lamb KM, Vonnahme LA, Dietz SE, Hohl RJ. Inhibition of geranylgeranyl diphosphate synthase induces apoptosis through multiple mechanisms and displays synergy with inhibition of other isoprenoid biosynthetic enzymes. J Pharmacol Exp Ther. 2008 Mar; 324(3):1028-36. PMID: 18083912.
      View in: PubMed
    57. Hamadmad SN, Hohl RJ. Erythropoietin stimulates cancer cell migration and activates RhoA protein through a mitogen-activated protein kinase/extracellular signal-regulated kinase-dependent mechanism. J Pharmacol Exp Ther. 2008 Mar; 324(3):1227-33. PMID: 18079357.
      View in: PubMed
    58. Wiemer AJ, Yu JS, Lamb KM, Hohl RJ, Wiemer DF. Mono- and dialkyl isoprenoid bisphosphonates as geranylgeranyl diphosphate synthase inhibitors. Bioorg Med Chem. 2008 Jan 01; 16(1):390-9. PMID: 17905588.
      View in: PubMed
    59. Miller AA, Murry DJ, Owzar K, Hollis DR, Lewis LD, Kindler HL, Marshall JL, Villalona-Calero MA, Edelman MJ, Hohl RJ, Lichtman SM, Ratain MJ. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol. 2007 Jul 20; 25(21):3055-60. PMID: 17634483.
      View in: PubMed
    60. Hohl RJ. Clinical pharmacology: bridging discovery and practice. Clin Pharmacol Ther. 2007 Jun; 81(6):783-5. PMID: 17505487.
      View in: PubMed
    61. Hamadmad SN, Hohl RJ. Lovastatin suppresses erythropoietin receptor surface expression through dual inhibition of glycosylation and geranylgeranylation. Biochem Pharmacol. 2007 Aug 15; 74(4):590-600. PMID: 17586475.
      View in: PubMed
    62. Widness JA, Schmidt RL, Hohl RJ, Goldman FD, Al-Huniti NH, Freise KJ, Veng-Pedersen P. Change in erythropoietin pharmacokinetics following hematopoietic transplantation. Clin Pharmacol Ther. 2007 Jun; 81(6):873-9. PMID: 17429351; PMCID: PMC2880326.
    63. Xing D, Murry DJ, Schmidt MS, Hohl RJ, Martins JB. Lovastatin specifically prevents focal ischemic ventricular tachycardia due to triggered activity. Heart Rhythm. 2007 May; 4(5):629-37. PMID: 17467633.
      View in: PubMed
    64. Maalouf MA, Wiemer AJ, Kuder CH, Hohl RJ, Wiemer DF. Synthesis of fluorescently tagged isoprenoid bisphosphonates that inhibit protein geranylgeranylation. Bioorg Med Chem. 2007 Mar 01; 15(5):1959-66. PMID: 17254791.
      View in: PubMed
    65. Wiemer AJ, Tong H, Swanson KM, Hohl RJ. Digeranyl bisphosphonate inhibits geranylgeranyl pyrophosphate synthase. Biochem Biophys Res Commun. 2007 Feb 23; 353(4):921-5. PMID: 17208200.
      View in: PubMed
    66. Mente NR, Wiemer AJ, Neighbors JD, Beutler JA, Hohl RJ, Wiemer DF. Total synthesis of (R,R,R)- and (S,S,S)-schweinfurthin F: differences of bioactivity in the enantiomeric series. Bioorg Med Chem Lett. 2007 Feb 15; 17(4):911-5. PMID: 17236766.
      View in: PubMed
    67. Shull LW, Wiemer AJ, Hohl RJ, Wiemer DF. Synthesis and biological activity of isoprenoid bisphosphonates. Bioorg Med Chem. 2006 Jun 15; 14(12):4130-6. PMID: 16517172.
      View in: PubMed
    68. Swanson KM, Hohl RJ. Anti-cancer therapy: targeting the mevalonate pathway. Curr Cancer Drug Targets. 2006 Feb; 6(1):15-37. PMID: 16475974.
      View in: PubMed
    69. Murthy S, Tong H, Hohl RJ. Regulation of fatty acid synthesis by farnesyl pyrophosphate. J Biol Chem. 2005 Dec 23; 280(51):41793-804. PMID: 16221687.
      View in: PubMed
    70. Hamadmad SN, Henry MK, Hohl RJ. Erythropoietin receptor signal transduction requires protein geranylgeranylation. J Pharmacol Exp Ther. 2006 Jan; 316(1):403-9. PMID: 16203826.
      View in: PubMed
    71. Holstein SA, Knapp HR, Clamon GH, Murry DJ, Hohl RJ. Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies. Cancer Chemother Pharmacol. 2006 Jan; 57(2):155-64. PMID: 16133537.
      View in: PubMed
    72. Lewis KA, Holstein SA, Hohl RJ. Lovastatin alters the isoprenoid biosynthetic pathway in acute myelogenous leukemia cells in vivo. Leuk Res. 2005 May; 29(5):527-33. PMID: 15755505.
      View in: PubMed
    73. Tong H, Holstein SA, Hohl RJ. Simultaneous determination of farnesyl and geranylgeranyl pyrophosphate levels in cultured cells. Anal Biochem. 2005 Jan 01; 336(1):51-9. PMID: 15582558.
      View in: PubMed
    74. Kim M, Kleckley TS, Wiemer AJ, Holstein SA, Hohl RJ, Wiemer DF. Synthesis and activity of fluorescent isoprenoid pyrophosphate analogues. J Org Chem. 2004 Nov 26; 69(24):8186-93. PMID: 15549786.
      View in: PubMed
    75. Henry MK, Nimbalkar D, Hohl RJ, Quelle FW. Cytokine-induced phosphoinositide 3-kinase activity promotes Cdk2 activation in factor-dependent hematopoietic cells. Exp Cell Res. 2004 Sep 10; 299(1):257-66. PMID: 15302592.
      View in: PubMed
    76. Burns CP, Halabi S, Clamon G, Kaplan E, Hohl RJ, Atkins JN, Schwartz MA, Wagner BA, Paskett E. Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia. Cancer. 2004 Jul 15; 101(2):370-8. PMID: 15241836.
      View in: PubMed
    77. Bailey HH, Wilding G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, Marnocha R, Holstein SA, Stewart J, Lewis KA, Hohl RJ. A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days. Cancer Chemother Pharmacol. 2004 Oct; 54(4):368-76. PMID: 15205914.
      View in: PubMed
    78. Veng-Pedersen P, Chapel S, Al-Huniti NH, Schmidt RL, Sedars EM, Hohl RJ, Widness JA. Pharmacokinetic tracer kinetics analysis of changes in erythropoietin receptor population in phlebotomy-induced anemia and bone marrow ablation. Biopharm Drug Dispos. 2004 May; 25(4):149-56. PMID: 15108217.
      View in: PubMed
    79. Holstein SA, Hohl RJ. Isoprenoids: remarkable diversity of form and function. Lipids. 2004 Apr; 39(4):293-309. PMID: 15357017.
      View in: PubMed
    80. Venook AP, Enders Klein C, Fleming G, Hollis D, Leichman CG, Hohl R, Byrd J, Budman D, Villalona M, Marshall J, Rosner GL, Ramirez J, Kastrissios H, Ratain MJ. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol. 2003 Dec; 14(12):1783-90. PMID: 14630685.
      View in: PubMed
    81. Ownby SE, Hohl RJ. Isoprenoid alcohols restore protein isoprenylation in a time-dependent manner independent of protein synthesis. Lipids. 2003 Jul; 38(7):751-9. PMID: 14506838.
      View in: PubMed
    82. Veng-Pedersen P, Chapel S, Al-Huniti NH, Schmidt RL, Sedars EM, Hohl RJ, Widness JA. A differential pharmacokinetic analysis of the erythropoietin receptor population in newborn and adult sheep. J Pharmacol Exp Ther. 2003 Aug; 306(2):532-7. PMID: 12750427.
      View in: PubMed
    83. Holstein SA, Wohlford-Lenane CL, Wiemer DF, Hohl RJ. Isoprenoid pyrophosphate analogues regulate expression of Ras-related proteins. Biochemistry. 2003 Apr 22; 42(15):4384-91. PMID: 12693933.
      View in: PubMed
    84. Holstein SA, Hohl RJ. Monoterpene regulation of Ras and Ras-related protein expression. J Lipid Res. 2003 Jun; 44(6):1209-15. PMID: 12671036.
      View in: PubMed
    85. Lee CK, deMagalhaes-Silverman M, Hohl RJ, Hayashi M, Buatti J, Wen BC, Schlueter A, Strauss RG, Gingrich RD. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft. Bone Marrow Transplant. 2003 Jan; 31(2):121-8. PMID: 12621494.
      View in: PubMed
    86. Chen X, Wiemer AJ, Hohl RJ, Wiemer DF. Stereoselective synthesis of the 5'-hydroxy-5'-phosphonate derivatives of cytidine and cytosine arabinoside. J Org Chem. 2002 Dec 27; 67(26):9331-9. PMID: 12492335.
      View in: PubMed
    87. Holstein SA, Wohlford-Lenane CL, Hohl RJ. Isoprenoids influence expression of Ras and Ras-related proteins. Biochemistry. 2002 Nov 19; 41(46):13698-704. PMID: 12427032.
      View in: PubMed
    88. Lee CK, de Magalhaes-Silverman M, Hohl RJ, Hayashi M, Buatti J, Wen BC, Schlueter A, Strauss RG, Gingrich RD. Prophylactic T cell infusion after T cell-depleted bone marrow transplantation in patients with refractory lymphoma. Bone Marrow Transplant. 2002 Apr; 29(7):615-20. PMID: 11979313.
      View in: PubMed
    89. Lee CK, de Magalhaes-Silverman M, Hayashi M, Schlueter A, Strauss RG, Hohl RJ, Gingrich RD. A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy with stem cell transplantation. Bone Marrow Transplant. 2002 Apr; 29(8):647-52. PMID: 12180108.
      View in: PubMed
    90. Kang J, Kumar V, Yang D, Chowdhury PR, Hohl RJ. Cyclodextrin complexation: influence on the solubility, stability, and cytotoxicity of camptothecin, an antineoplastic agent. Eur J Pharm Sci. 2002 Mar; 15(2):163-70. PMID: 11849913.
      View in: PubMed
    91. Ownby SE, Hohl RJ. Farnesol and geranylgeraniol: prevention and reversion of lovastatin-induced effects in NIH3T3 cells. Lipids. 2002 Feb; 37(2):185-92. PMID: 11908910.
      View in: PubMed
    92. Holstein SA, Wohlford-Lenane CL, Hohl RJ. Consequences of mevalonate depletion. Differential transcriptional, translational, and post-translational up-regulation of Ras, Rap1a, RhoA, AND RhoB. J Biol Chem. 2002 Mar 22; 277(12):10678-82. PMID: 11788600.
      View in: PubMed
    93. Holstein SA, Hohl RJ. Synergistic interaction of lovastatin and paclitaxel in human cancer cells. Mol Cancer Ther. 2001 Dec; 1(2):141-9. PMID: 12467231.
      View in: PubMed
    94. Holstein SA, Hohl RJ. Interaction of cytosine arabinoside and lovastatin in human leukemia cells. Leuk Res. 2001 Aug; 25(8):651-60. PMID: 11397469.
      View in: PubMed
    95. Chapel S, Veng-Pedersen P, Hohl RJ, Schmidt RL, McGuire EM, Widness JA. Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway. J Pharmacol Exp Ther. 2001 Aug; 298(2):820-4. PMID: 11454947.
      View in: PubMed
    96. Kumar V, Kang J, Hohl RJ. Improved dissolution and cytotoxicity of camptothecin incorporated into oxidized-cellulose microspheres prepared by spray drying. Pharm Dev Technol. 2001 Aug; 6(3):459-67. PMID: 11485187.
      View in: PubMed
    97. Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K, Horak I, Tidwell ML, Liesveld J, Kottke TJ, Ange D, Buddharaju L, Gojo I, Highsmith WE, Belly RT, Hohl RJ, Rybak ME, Thibault A, Rosenblatt J. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood. 2001 Jun 01; 97(11):3361-9. PMID: 11369625.
      View in: PubMed
    98. Cermak DM, Wiemer DF, Lewis K, Hohl RJ. 2-(Acyloxy)ethylphosphonate analogues of prenyl pyrophosphates: synthesis and biological characterization. Bioorg Med Chem. 2000 Dec; 8(12):2729-37. PMID: 11131164.
      View in: PubMed
    99. Jung KY, Hohl RJ, Wiemer AJ, Wiemer DF. Synthesis of phosphonate derivatives of uridine, cytidine, and cytosine arabinoside. Bioorg Med Chem. 2000 Oct; 8(10):2501-9. PMID: 11058045.
      View in: PubMed
    100. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000 Sep; 83(5):588-93. PMID: 10944597; PMCID: PMC2363506.
    101. Venook AP, Egorin MJ, Rosner GL, Hollis D, Mani S, Hawkins M, Byrd J, Hohl R, Budman D, Meropol NJ, Ratain MJ. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol. 2000 Jul; 18(14):2780-7. PMID: 10894879.
      View in: PubMed
    102. Burns CP, Halabi S, Clamon GH, Hars V, Wagner BA, Hohl RJ, Lester E, Kirshner JJ, Vinciguerra V, Paskett E. Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and leukemia group B study 9473. Clin Cancer Res. 1999 Dec; 5(12):3942-7. PMID: 10632323.
      View in: PubMed
    103. Lee CK, Gingrich RD, deMagalhaes-Silverman M, Hohl RJ, Joyce JK, Scott SD, Wen BC, Schlueter A. Prophylactic reinfusion of T cells for T cell-depleted allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 1999; 5(1):15-27. PMID: 10232737.
      View in: PubMed
    104. Gingrich RD, Lee CK, Hohl R, Joyce J, Burns LJ, Tamaki K, Wen BC, Scott S. A novel four-drug ablative regimen with hemopoietic stem cell rescue for patients with breast cancer: a phase II study. Biol Blood Marrow Transplant. 1999; 5(2):86-93. PMID: 10371360.
      View in: PubMed
    105. Hohl RJ, Sherburne AR, Feeley JE, Huisman TH, Burns CP. Low pulse oximeter-measured hemoglobin oxygen saturations with hemoglobin Cheverly. Am J Hematol. 1998 Nov; 59(3):181-4. PMID: 9798654.
      View in: PubMed
    106. Holstein SA, Cermak DM, Wiemer DF, Lewis K, Hohl RJ. Phosphonate and bisphosphonate analogues of farnesyl pyrophosphate as potential inhibitors of farnesyl protein transferase. Bioorg Med Chem. 1998 Jun; 6(6):687-94. PMID: 9681134.
      View in: PubMed
    107. Venook AP, Egorin MJ, Rosner GL, Brown TD, Jahan TM, Batist G, Hohl R, Budman D, Ratain MJ, Kearns CM, Schilsky RL. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol. 1998 May; 16(5):1811-9. PMID: 9586895.
      View in: PubMed
    108. Hohl RJ, Lewis KA, Cermak DM, Wiemer DF. Stereochemistry-dependent inhibition of RAS farnesylation by farnesyl phosphonic acids. Lipids. 1998 Jan; 33(1):39-46. PMID: 9470172.
      View in: PubMed
    109. Lewis KA, Hohl RJ. Modulation of RAS expression in human malignant cells by dietary supplements. Nutrition. 1997 Oct; 13(10):921-3. PMID: 9357036.
      View in: PubMed
    110. Goldman F, Hohl RJ, Crabtree J, Lewis-Tibesar K, Koretzky G. Lovastatin inhibits T-cell antigen receptor signaling independent of its effects on ras. Blood. 1996 Dec 15; 88(12):4611-9. PMID: 8977253.
      View in: PubMed
    111. Lee CK, Harman GS, Hohl RJ, Gingrich RD. Fatal cyclophosphamide cardiomyopathy: its clinical course and treatment. Bone Marrow Transplant. 1996 Sep; 18(3):573-7. PMID: 8879620.
      View in: PubMed
    112. Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, Hohl RJ, Trepel J, Liang B, Patronas N, Venzon DJ, Reed E, Myers CE. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res. 1996 Mar; 2(3):483-91. PMID: 9816194.
      View in: PubMed
    113. Hohl RJ. Monoterpenes as regulators of malignant cell proliferation. Adv Exp Med Biol. 1996; 401:137-46. PMID: 8886132.
      View in: PubMed
    114. Clamon GH, Riggs CE, Dreicer R, Hohl RJ. Phase II trial of edatrexate in patients with metastatic colorectal cancer. Invest New Drugs. 1996; 13(4):359-61. PMID: 8824357.
      View in: PubMed
    115. Hohl RJ, Lewis K. Differential effects of monoterpenes and lovastatin on RAS processing. J Biol Chem. 1995 Jul 21; 270(29):17508-12. PMID: 7615555.
      View in: PubMed
    116. Lee CK, Gingrich RD, Hohl RJ, Ajram KA. Engraftment syndrome in autologous bone marrow and peripheral stem cell transplantation. Bone Marrow Transplant. 1995 Jul; 16(1):175-82. PMID: 7581119.
      View in: PubMed
    117. Hohl RJ, Larson RA, Mannickarottu V, Yachnin S. Inhibition of hydroxymethylglutaryl coenzyme A reductase activity induces a paradoxical increase in DNA synthesis in myeloid leukemia cells. Blood. 1991 Mar 01; 77(5):1064-70. PMID: 1995091.
      View in: PubMed
    118. GRUBER W, HOHL R, WIELAND T. Hydroquinone monophosphates and oxidative phosphorylation. Biochem Biophys Res Commun. 1963 Jul 26; 12:242-6. PMID: 13950882.
      View in: PubMed
    Hohl's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Physical Neighbors Expand Description
    _